Truist Lifts Immunovant (IMVT) PT to $22 on Updated 2026 Financial Modeling

Core Viewpoint - Immunovant Inc. (NASDAQ:IMVT) is considered a promising stock under $50, with recent analyst upgrades indicating a positive shift in market sentiment regarding its potential in treating Graves' disease [1][2]. Analyst Ratings and Price Targets - Truist analyst Danielle Brill raised the price target for Immunovant to $22 from $16 while maintaining a Hold rating, indicating that the core fundamental outlook remains unchanged through 2025 [1]. - Wolfe Research upgraded Immunovant from Peer Perform to Outperform with a price target of $50, citing a shift in market sentiment and increased investor appreciation for the Graves' disease treatment space [2]. - Guggenheim analyst Yatin Suneja maintained a Buy rating but lowered the price target to $41 from $44, following a $550 million equity offering that may lead to stock dilution, though it strengthens the balance sheet and extends the cash runway [3]. Company Overview - Immunovant Inc. is a clinical-stage immunology company focused on developing monoclonal antibodies for the treatment of autoimmune diseases [4].